PET imaging in oncology

Ido, 1977, Flurination with F2. A convenient synthesis of 2-deoxy-2-fluoro-D-glucose, J Org Chem, 42, 2341, 10.1021/jo00433a037 Warburg, 1931, The Metabolism of Tumors Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 Weber, 1977, Enzymology of cancer cells (first part), New Engl J Med, 296, 486, 10.1056/NEJM197703032960905 Weber, 1977, Enzymology of cancer cells (second part), New Engl J Med, 296, 541, 10.1056/NEJM197703102961005 Weber, 1983, Biochemical strategy of cancer cells and the design of chemotherapy. GHA Clowes Memorial Lecture, Cancer Res, 43, 3466 Weber, 1984, Molecular events leading to enhanced glucose transport in rous sarcoma virus—transformed cells, 43, 2246 Flier, 1987, Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes, Science, 235, 1492, 10.1126/science.3103217 Hiraki, 1988, Growth factors rapidly induce expression of the glucose transporter gene, J Biol Chem, 263, 13655, 10.1016/S0021-9258(18)68291-2 Higashi, 1997, Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study, J Nucl Med, 38, 1337 Reske, 1997, Overexpression of glucose transporter and increased FDG uptake in pancreatic carcinoma, J Nucl Med, 38, 1344 Brown, 1993, Overexpression of glut-1 glucose transporter in human breast cancer: An immunohistochemical study, Cancer, 72, 2979, 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X Younes, 1997, Overexpression of glut-1 and glut-3 in stage I non-small cell lung cancer is associated with poor survival, Cancer, 80, 1046, 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7 Brown, 1999, Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer, J Nucl Med, 40, 556 Knox, 1970, Hexokinase, differentiation and growth rates of transplanted rat tumors, Cancer Res, 30, 2240 Monakhov, 1978, Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues, J Natl Cancer Inst, 61, 27, 10.1093/jnci/61.1.27 Kern, 1987, Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-D-glucose, Surgery, 102, 380 Weber, 1955, Glucose-6-phosphatase activity in normal, precancerous and neoplastic tissues, Cancer Res, 15, 105 Di Chiro, 1982, Glucose utilization of cerebral gliomas measured by (18F) fluorodeoxy-glucose and positron emission tomography, Neurology, 32, 1323, 10.1212/WNL.32.12.1323 Som, 1980, A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection, J Nucl Med, 21, 670 Di Chiro, 1987, Positron emission tomography using (18F) fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool, Invest Radiol, 22, 360, 10.1097/00004424-198705000-00002 Gallagher, 1977, Radiopharmaceuticals XXVII. 18F-labled 2-deoxy-2fluoro-D-Glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: Tissue distribution and imaging studies in animals, J Nucl Med, 18, 990 Gallagher, 1978, Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of (18F)2-deoxy-2-fluoro-D-glucose, J Nucl Med, 19, 1154 Koeppe, 1992, Instrumentation of positron emission tomography: Tomographs and data processing and display systems, Semin Nucl Med, 22, 162, 10.1016/S0001-2998(05)80144-8 Sorenson, 1987, Nuclear Medicine Tomography: Systems and Services Kirchner, 1996, Emission computed tomographic imaging Cherry, 1996, A high resolution PET scanner for imaging small animals, 1120 Karp, 1990, Continuousslice PENN-PET: A positron tomograph with volume imaging capability, J Nucl Med, 31, 617 State of the Art Clinical Full Positron Emission Tomograph, 1998 Halama, 1999, Imaging in nuclear medicine Landoni, 1999, Comparison of dual-head coincidence PET vs ring PET in tumor patients, J Nucl Med, 40, 1617 Yutani, 1999, Comparison of dual-head coincidence gamma camera FDG imaging with FDG-PET in detection of breast cancer and axillary lymph node metastasis, J Nucl Med, 40, 1003 Stokkel, 1998, Fluorine-18-FDG detection of laryngeal cancer postradiotherapy using dual-head coincidence imaging, J Nucl Med, 39, 1385 Ginsberg, 1997, Non-small cell lung cancer Parker, 1996, Cancer statistics, CA Cancer J Clin, 46, 5, 10.3322/canjclin.46.1.5 Lowe, 1995, Application of PET in oncology imaging Siegelman, 1986, Solitary pulmonary nodules: CT assessment, Radiology, 160, 307, 10.1148/radiology.160.2.3726105 Swensen, 1990, An integrated approach to evaluation of the solitary pulmonary nodule, 65, 173 Khouri, 1987, The solitary pulmonary nodule: Assessment, diagnosis and management, Chest, 91, 128, 10.1378/chest.91.1.128 Lowe, 1998, Positron emission tomography in lung cancer, Ann Thorac Surg, 65, 1821, 10.1016/S0003-4975(98)00106-4 Kubota, 1990, Differential diagnosis of lung tumor with positron emission tomography: A prospective study, J Nucl Med, 31, 1927 Dewan, 1993, Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules—potential role in evaluation and management, Chest, 104, 997, 10.1378/chest.104.4.997 Patz, 1993, Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning, Radiology, 188, 487, 10.1148/radiology.188.2.8327702 Duhaylongsod, 1995, Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxy-glucose positron emission tomography (FDG-PET), J Thorac Cardiovasc Surg, 110, 130, 10.1016/S0022-5223(05)80018-2 Bury, 1996, Evaluation of the solitary pulmonary nodule by positron emission tomography imaging, Eur Respir J, 9, 410, 10.1183/09031936.96.09030410 Knight, 1996, Evaluation of pulmonary lesions with FDG-PET comparison of findings in patients with and without a history of prior malignancy, Chest, 109, 982, 10.1378/chest.109.4.982 Gupta, 1996, Probability of malignancy, J Nucl Med, 37, 943 Lowe, 1997, Pulmonary abnormalities and PET data analysis: A retrospective study, Radiology, 202, 435, 10.1148/radiology.202.2.9015070 Worsley, 1997, Pulmonary nodules. Differential diagnosis using 18F-fluorodeoxyglucose single photon emission computed tomography, AJR Am J Roentgenol, 168, 771, 10.2214/ajr.168.3.9057532 Dewan, 1997, Likelihood of malignancy in a solitary pulmonary nodule comparison of bayesian analysis and results of FDG-PET scan, Chest, 112, 416, 10.1378/chest.112.2.416 Lowe, 1998, Prospective investigation of positron emission tomography in lung nodules, J Clin Oncol, 16, 1075, 10.1200/JCO.1998.16.3.1075 Dewan, 1995, PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis, Chest, 108, 441, 10.1378/chest.108.2.441 Winning, 1986, Interpretation of negative results in fine needle aspiration of discrete pulmonary lesions, Thorax, 41, 875, 10.1136/thx.41.11.875 Coleman, 1999, FDG imaging of lung nodules: A phantom study comparing SPECT, camera based PET and dedicated PET, Radiology, 210, 823, 10.1148/radiology.210.3.r99mr18823 Higashi, 1998, Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma, J Nucl Med, 39, 1016 Rege, 1993, Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose, Cancer, 72, 82, 10.1002/1097-0142(19930701)72:1<82::AID-CNCR2820720117>3.0.CO;2-3 Torizuka, 1999, Diabetes decreases FDG accumulation in primary lung cancer, Clin Pos Imag, 2, 281, 10.1016/S1095-0397(99)00029-1 Langen, 1993, The influence of plasma glucose levels on Fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas, J Nucl Med, 34, 355 Coleman, 1999, PET in lung cancer, J Nucl Med, 40, 814 Lababede, 1999, TNM staging of lung cancer, A quick reference chart. Chest, 115, 233 Valk, 1995, Staging non-small cell lung cancer by whole-body positron emission tomographic imaging, Ann Thorac Surg, 60, 1573, 10.1016/0003-4975(95)00752-0 Nestle, 1999, 18 F-deoxyglucose radiotherapy in lung cancer: High impact in patients with atelectasis, Int J Radiat Oncol Biol Phys, 44, 593, 10.1016/S0360-3016(99)00061-9 Patz, 1995, Thoracic nodal staging with PET imaging with FDG in patients with bronchogenic carcinoma, Chest, 108, 1617, 10.1378/chest.108.6.1617 Sasaki, 1996, The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with x-ray computed tomography, Eur J Nucl Med, 23, 741, 10.1007/BF00843701 Scott, 1996, Mediastinal lymph node staging of non-small cell lung cancer: A prospective comparison of computed tomography and positron emission tomography, J Thorac Cardiovasc Surg, 111, 642, 10.1016/S0022-5223(96)70317-3 Steinert, 1997, Non-small cell lung cancer: Nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling, Radiology, 202, 441, 10.1148/radiology.202.2.9015071 Bury, 1997, Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer, Eur Respir J, 10, 2529, 10.1183/09031936.97.10112529 Vansteenkiste, 1998, Lymph node staging in non-small cell lung cancer with FDG-PET scan: A prospective study of 690 lymph node stations from 68 patients, J Clin Oncol, 16, 2142, 10.1200/JCO.1998.16.6.2142 Heavey, 1986, The role of CT in staging radiographic T1 N0 M0 lung cancer, AJR Am J Roentgenol, 146, 285, 10.2214/ajr.146.2.285 McLoud, 1992, Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling, Radiology, 182, 319, 10.1148/radiology.182.2.1732943 Gdeedo, 1997, Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging, Eur Respir J, 10, 1547, 10.1183/09031936.97.10071547 Marom, 1999, Staging non-small cell lung cancer with whole-body PET, Radiology, 212, 803, 10.1148/radiology.212.3.r99se21803 Weder, 1998, Detection of extrathoracic metastases by positron emission tomography in lung cancer, Ann Thorac Surg, 66, 886, 10.1016/S0003-4975(98)00675-4 Oliver, 1984, Isolated adrenal masses in non-small cell bronchogenic carcinoma, Radiology, 153, 217, 10.1148/radiology.153.1.6473783 Dunnick, 1990, Adrenal imaging: Current status, AJR Am J Roentgenol, 154, 927, 10.2214/ajr.154.5.2108567 Porte, 1999, Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small-cell lung cancer?, Eur J Cardiothorac Surg, 15, 597, 10.1016/S1010-7940(99)00047-0 Erasmus, 1997, Evaluation of adrenal masses in patients with bronchogenic carcinoma using F18 fluorodeoxy-glucose positron emission tomography, AJR Am J Roentgenol, 168, 1357, 10.2214/ajr.168.5.9129444 Boland, 1995, Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-(F-18)-fluoro-2-deoxy-D-glucose, Radiology, 194, 131, 10.1148/radiology.194.1.7997539 Maurea, 1999, Imaging of adrenal tumors using FDG PET: Comparison of benign and malignant lesions, AJR Am J Roentgenol, 173, 25, 10.2214/ajr.173.1.10397094 Patz, 1994, Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-(18)-2-deoxy-D-glucose, Radiology, 191, 379, 10.1148/radiology.191.2.8153309 Inoue, 1995, Detecting recurrent or residual lung cancer with FDG-PET, J Nucl Med, 36, 788 Iosilevsky, 1985, Uptake of Gallium-67-citrate and [2-3H0 deoxyglucose in the tumor following chemotherapy and radiotherapy, J Nucl Med, 26, 278 Abe, 1990, Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: Preliminary study of lung cancer, Int J Radiat Oncol Biol Phys, 19, 1005, 10.1016/0360-3016(90)90026-G Hebert, 1996, Positron emisson tomography in the pretreatment evaluation and follow up of non-small cell lung cancer patients treated with radio-therapy: Preliminary findings, Am J Clin Oncol, 19, 416, 10.1097/00000421-199608000-00020 Ichiya, 1996, A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma, Ann Nucl Med, 10, 193, 10.1007/BF03165392 Vansteenkiste, 1998, Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small cell lung cancer: A prospective pilot study, Ann Oncol, 9, 1193, 10.1023/A:1008437915860 Cohen, 1997, Cancer of the colon and the rectum Falk, 1994, Positron emission tomography for preoperative staging of colorectal carcinoma, Dis Colon Rectum, 37, 153, 10.1007/BF02047538 Abdel-Nabi, 1998, Staging of primary colorectal carcinomas with Fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings, Radiology, 206, 755, 10.1148/radiology.206.3.9494497 Yasuda, 1998, F-18 FDG uptake in colonic adenoma, Clin Nucl Med, 23, 99, 10.1097/00003072-199802000-00008 Delbeke, 1999, Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma, J Nucl Med, 40, 591 Strauss, 1989, Recurrence of colorectal tumors: PET evaluation, Radiology, 170, 329, 10.1148/radiology.170.2.2783494 Vitola, 1996, Positron emission tomography to stage metastatic colorectal carcinoma to liver, Am J Surg, 171, 21, 10.1016/S0002-9610(99)80067-1 Ito, 1992, Recurrent rectal cancer and scar: Differentiation with PET and MR imaging, Radiology, 182, 549, 10.1148/radiology.182.2.1732979 Kim, 1992, Differentiation of residual or recurrent tumors from pos-treatment changes with F-18 FDG-PET, Radiographics, 12, 269, 10.1148/radiographics.12.2.1561416 Lai, 1996, The role of whole-body positron emission tomography with (18F) fluorode-oxyglucose in identifying operable colorectal cancer metastases to the liver, Arch Surg, 131, 703, 10.1001/archsurg.1996.01430190025007 Schiepers, 1995, Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging, Eur J Surg Oncol, 21, 517, 10.1016/S0748-7983(95)97046-0 Keogan, 1997, Local recurrence of rectal cancer: Evaluation with F-18 fluorodeoxyglucose PET imaging, Abdom Imaging, 22, 332, 10.1007/s002619900202 Ogunbiyi, 1997, Detection of recurrent and metastatic colorectal cancer: Comparison with position emission tomography and computed tomography, Ann Surg Oncol, 4, 613, 10.1007/BF02303744 Delbeke, 1997, Staging recurrent metastic colorectal carcinoma with PET, J Nucl Med, 38, 1196 Valk, 1999, Whole-body PET imaging with (18F) fluorodeoxyglucose in management of recurrent colorectal cancer, Arch Surg, 134, 503, 10.1001/archsurg.134.5.503 Grabbe, 1985, Local recurrence after sphincter-saving resection for rectal and rectosigmoid carcinoma: Value of various diagnostic methods, Radiology, 155, 305, 10.1148/radiology.155.2.3983380 Flanagan, 1998, Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer, Ann Surg, 227, 319, 10.1097/00000658-199803000-00001 Haberkorn, 1991, PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy, J Nucl Med, 32, 1485 Findlay, 1996, Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil, J Clin Oncol, 4, 700, 10.1200/JCO.1996.14.3.700 Vitola, 1996, Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization, Cancer, 78, 2216, 10.1002/(SICI)1097-0142(19961115)78:10<2216::AID-CNCR25>3.0.CO;2-0 Strauss, 1996, Fluorine-18-deoxyglucose and falsepositive results: A major problem in the diagnosis of oncological patients, Eur J Nucl Med, 23, 1409, 10.1007/BF01367602 Shipp, 1997, Non-Hodgkin's lymphoma and hodgkin's disease Shipp, 1993, The international non-Hodgkin's lymphoma prognostic factor project: A predictive model for aggressive non-Hodgkin's lymphoma, N Engl J Med, 329, 987, 10.1056/NEJM199309303291402 Munker, 1995, Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases, Cancer, 76, 1460, 10.1002/1097-0142(19951015)76:8<1460::AID-CNCR2820760825>3.0.CO;2-Y Canellos, 1988, Residual mass in lymphoma may not be residual disease, J Clin Oncol, 6, 931, 10.1200/JCO.1988.6.6.931 Front, 1990, Gallium-67 SPECT before and after treatment of lymphoma, Radiology, 175, 515, 10.1148/radiology.175.2.2183289 Ben-Haim, 1996, Utility of Gallium-67-scintigraphy in low-grade non-Hodgkin's lymphoma, J Clin Oncol, 14, 1936, 10.1200/JCO.1996.14.6.1936 Front, 1992, Lymphoma: Predictive value of Ga67 scintigraphy after treatment, Radiology, 182, 359, 10.1148/radiology.182.2.1732950 Front, 1993, Early detection of lymphoma recurrence with Gallium-67 scintigraphy, J Nucl Med, 34, 2101 Front, 1999, Hodgkin's disease: Prediction of outcome with Ga67 scintigraphy after one cycle of chemotherapy, Radiology, 210, 487, 10.1148/radiology.210.2.r99fe07487 Paul, 1987, Comparison of Fluorine-18-fluorodeoxyglucose and Gallium-67 citrate imaging for detection of lymphoma, J Nucl Med, 28, 288 Okada, 1991, The use of FDG-PET in the detection and management of malignant, J Nucl Med, 32, 686 Hoekstra, 1993, Early treatment response in malignant lymphoma as determined by planar Fluorine-18-fluorodeoxyglucose scintigraphy, J Nucl Med, 34, 1706 Hoh, 1997, Whole body FDG-PET imaging for staging of Hodgkin's disease and lymphoma, J Nucl Med, 38, 343 Lapela, 1995, Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and Fluorine-18-fluorodeoxyglucose, Blood, 86, 3522, 10.1182/blood.V86.9.3522.bloodjournal8693522 Okada, 1992, Positron emission tomography using Fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferate activity, J Nucl Med, 33, 325 Leskinen-Kallio, 1991, Uptake of Carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study, J Nucl Med, 32, 1211 Newman, 1994, Imaging of lymphoma with PET with F-18-fluorodeoxyglucose: Correlation with CT, Radiology, 190, 111, 10.1148/radiology.190.1.8259386 Okada, 1994, FDG-PET for predicting the prognosis of malignant lymphoma, Ann Nucl Med, 8, 187, 10.1007/BF03164996 Stumpe, 1998, Whole body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography, Eur J Nucl Med, 25, 721, 10.1007/s002590050275 Moog, 1997, Lymphoma: Role of whole body FDG-PET in nodal staging, Radiology, 203, 795, 10.1148/radiology.203.3.9169707 Moog, 1998, Extranodal malignant lymphoma: Detection with FDG PET versus CT, Radiology, 206, 475, 10.1148/radiology.206.2.9457202 Bangerter, 1998, Whole-body 2-(F18)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease, Ann Oncol, 9, 1117, 10.1023/A:1008486928190 Jerusalem, 1999, Whole-body F18 FDG-PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma, Nucl Med Commun, 20, 13, 10.1097/00006231-199901000-00004 Moog, 1998, F18-fluorodeoxyglucose positron emission tomography as a new approach to detect lymphomatous bone marrow, J Clin Oncol, 16, 603, 10.1200/JCO.1998.16.2.603 Romer, 1998, Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with flurodeoxyglucose, Blood, 91, 4464 Hoekstra, 1993, Early response monitoring in malignant lymphoma using Fluorine-18-fluorodeoxyglucose single photon emission tomography, Eur J Nucl Med, 20, 1214, 10.1007/BF00171020 Surbone, 1988, Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management, J Clin Oncol, 6, 1832, 10.1200/JCO.1988.6.12.1832 Cremerius, 1998, Positron emission tomography with F18-FDG to detect residual disease after therapy for malignant lymphoma, Nucl Med Commun, 19, 1055, 10.1097/00006231-199811000-00005 Zinzani, 1999, The role of positron emission tomography (PET) in the management of lymphoma patients, Ann Oncol, 10, 1181, 10.1023/A:1008327127033 Jerusalem, 1999, Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging, Blood, 94, 429, 10.1182/blood.V94.2.429 Alavi, 1998, Detection of unsuspected recurrent lymphoma with fluorodeoxyglucose positron emission tomographic imaging after induction chemotherapy: A case study, Am J Clin Oncol, 21, 126, 10.1097/00000421-199804000-00005 Holder, 1998, Effectiveness of positron emission tomography for the detection of melanoma metastases, Ann Surg, 227, 764, 10.1097/00000658-199805000-00017 Holder, 1998, Effectiveness of positron emission tomography for the detection of melanoma metastases, Ann Surg, 227, 769, 10.1097/00000658-199805000-00017 Rinne, 1998, Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients, Cancer, 82, 1664, 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2 Steinert, 1995, Malignant melanoma: Staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose, Radiology, 195, 705, 10.1148/radiology.195.3.7753998 Damian, 1996, Positron emission tomography in the detection and management of metastatic melanoma, Melanoma Res, 6, 325, 10.1097/00008390-199608000-00008 Wagner, 1999, Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy, J Clin Oncol, 17, 1508, 10.1200/JCO.1999.17.5.1508 Morton, 1992, Technical details of intraoperative lymphatic mapping for early stage melanoma, Arch Surg, 177, 392, 10.1001/archsurg.1992.01420040034005 Uren, 1993, Lymphoscintigraphy in high-risk melanoma of the trunk: Predicting draining node groups, defining lymphatic channels and locating the sentinel node, J Nucl Med, 34, 1435 Pijpers, 1995, The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma, Eur J Nucl Med, 22, 1238, 10.1007/BF00801606 Reintgen, 1994, The orderly progression of melanoma nodal metastases, Ann Surg, 220, 759, 10.1097/00000658-199412000-00009 Macfarlane, 1998, Prospective evaluation of 2-(18F)-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma, J Clin Oncol, 16, 1770, 10.1200/JCO.1998.16.5.1770 Blessing, 1995, Positron emission tomography and ultrasonography: A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma, Arch Dermatol, 131, 1394, 10.1001/archderm.1995.01690240048008 Keyes, 1997, FDG-PET in head and neck cancer, AJR Am J Roentgenol, 169, 1663, 10.2214/ajr.169.6.9393187 Schantz, 1997, Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity and oropharynx; Sessions RB, Harrison LB, Forastiere AA: Tumors of the larynx and hypopharynx Vokes, 1993, Head and neck cancer, N Engl J Med, 328, 184, 10.1056/NEJM199301213280306 Minn, 1988, Evaluation of treatment response to radiotherapy in head and neck cancer with Fluorine-18 fluorodeoxyglucose, J Nucl Med, 29, 1521 Jabour, 1993, Extracranial head and neck: PET imaging with 2-(F-18) fluoro-2-deoxy-D-glucose and MR imaging correlation, Radiology, 186, 27, 10.1148/radiology.186.1.8416578 Greven, 1994, Positron emission tomography of patients with head and neck carcinoma before and after high dose inrradiation, Cancer, 74, 1355, 10.1002/1097-0142(19940815)74:4<1355::AID-CNCR2820740428>3.0.CO;2-I Paulus, 1998, 18 FDG-PET for the assessment of primary had and neck tumors: Clinical computed tomography and histopathological correlation in 38 patients, Laryngoscope, 108, 1578, 10.1097/00005537-199810000-00029 Adams, 1998, Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer, Eur J Nucl Med, 25, 1255, 10.1007/s002590050293 Kitagawa, 1999, FDG-PET to evaluate combined intra-arterial chemotherapy of head and neck neoplasms, J Nucl Med, 40, 1132 Mukherji, 1996, Occult primary tumors of the head and neck: Detection with 2-(F-18) fluoro-2-deoxy-D-glucose SPECT, Radiology, 199, 761, 10.1148/radiology.199.3.8638002 Assar, 1999, Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors, Radiology, 210, 177, 10.1148/radiology.210.1.r99ja48177 Kole, 1998, Detection of unknown occult primary tumors using positron emission tomography, Cancer, 82, 1160, 10.1002/(SICI)1097-0142(19980315)82:6<1160::AID-CNCR22>3.0.CO;2-3 Greco, 1997, Cancer of unknown primary site Greven, 1999, Occult primary tumors of the head and neck. Lack of benefit from positron emission tomography imaging with 2-(F-18) fluoro-2-deoxy-D-glucose, Cancer, 86, 114, 10.1002/(SICI)1097-0142(19990701)86:1<114::AID-CNCR16>3.0.CO;2-E Braams, 1995, Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI, J Nucl Med, 36, 211 Benchaou, 1996, The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer, Acta Otolaryngol, 116, 332, 10.3109/00016489609137852 Rege, 1994, Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers, Cancer, 73, 3047, 10.1002/1097-0142(19940615)73:12<3047::AID-CNCR2820731225>3.0.CO;2-# Laubenbacher, 1995, Comparison of Fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous cell carcinomas, J Nucl Med, 36, 1747 McGuirt, 1995, Comparative diagnostic study of head and neck metastases using positron emission tomography, Laryngoscope, 105, 373, 10.1288/00005537-199504000-00006 Lowe, 1999, Head and neck cancer nodal staging Myers, 1998, Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer, J Otolaryngol, 27, 342 Myers, 1998, Positron emission tomography in the evaluation of the No neck, Laryngoscope, 108, 232, 10.1097/00005537-199802000-00014 Lowe, 1997, Evaluation of chemotherapy response in patients with advanced head and neck cancer using (F-18) fluorodeoxyglucose positron emission tomography, Head Neck, 19, 666, 10.1002/(SICI)1097-0347(199712)19:8<666::AID-HED4>3.0.CO;2-3 Brun, 1997, Early prediction of treatment outcome in head and neck cancer with 2–18 FDG PET, Acta Oncol, 36, 741, 10.3109/02841869709001348 Minn, 1997, Prediction of survival with Fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer, J Nucl Med, 38, 1907 Rege, 1993, Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: Quantitation with PET, Radiology, 189, 807, 10.1148/radiology.189.3.8234708 Kao, 1998, Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography, J Clin Oncol, 16, 3550, 10.1200/JCO.1998.16.11.3550 Anzai, 1996, Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-(F-18-) fluoro-D-glucose PET and MR imaging diagnosis, Radiology, 200, 135, 10.1148/radiology.200.1.8657901 Fischbein, 1998, Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck, AJNR Am J Neuroradiol, 19, 1189 Harris, 1997, Malignant tumors of the breast Wahl, 1991, Primary and metastatic breast carcinoma: Initial evaluation with PET with the radiolabeled glucose analog 2-(F-18)-fluorodeoxy-2-D-glucose (FDG), Radiology, 179, 765, 10.1148/radiology.179.3.2027989 Tse, 1992, The application of positron emission tomography imaging with fluorodeoxyglucose to the evaluation of breast disease, Ann Surg, 216, 27, 10.1097/00000658-199207000-00005 Nieweg, 1993, Positron emission tomography with Fluorine-18-deoxyglucose in the detection and staging of breast cancer, Cancer, 71, 3920, 10.1002/1097-0142(19930615)71:12<3920::AID-CNCR2820711220>3.0.CO;2-N Adler, 1993, Evaluation of breast masses and axillary lymph-nodes with (F-18)-2-deoxy-2-fluoro-D-glucose PET, Radiology, 187, 743, 10.1148/radiology.187.3.8497624 Hoh, 1993, Cancer detection, J Comput Assist Tomogr, 17, 582, 10.1097/00004728-199307000-00012 Nieweg, 1993, Positron emission tomography of glucose metabolism in breast cancer: Potential for tumor detection, staging and evaluation of chemotherapy, Ann N Y Acad Sci, 689, 423, 10.1111/j.1749-6632.1993.tb17236.x Dehdashti, 1995, Positron tomography assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays, J Nucl Med, 36, 1766 Schiedhauer, 1996, Qualitative (18F) FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability, Eur J Nucl Med, 23, 618, 10.1007/BF00834522 Avril, 1996, Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose, J Clin Oncol, 14, 1848, 10.1200/JCO.1996.14.6.1848 Holle, 1996, Investigations of breast tumors with Fluorine-18-fluorodeoxyglucose and SPECT, J Nucl Med, 37, 615 Palmed, 1997, Comparison of Fluorine-18 fluorodeoxyglucose positron emission tomography and Technetium-99m methoxy isobutyglisonitrile scintimammography in the detection of breast tumors, Eur J Nucl Med, 24, 1138 Wahl, 1994, Detection of breast cancer in women after augmentation mammoplasty using Fluorine-18-fluorodeoxyglucose-PET, J Nucl Med, 35, 872 Delbeke, 1999, Oncological applications of FDG-PET imaging, J Nucl Med, 40, 1706 Boerner, 1999, Optimal scan time for Fluorine-18-fluorodeoxyglucose positron emission tomography in breast cancer, Eur J Nucl Med, 26, 226, 10.1007/s002590050381 Adler, 1997, Axillary lymph-node metastases: Screening with (F-18) 2-deoxy-2-fluoro-D-glucose (FDG) PET, Radiology, 203, 323, 10.1148/radiology.203.2.9114082 Utech, 1996, Prospective evaluation of Fluorine-18-fluorodeoxyglucose positon emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry, Eur J Nucl Med, 23, 1588, 10.1007/BF01249621 Avril, 1996, Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose, J Natl Cancer Inst, 88, 1204, 10.1093/jnci/88.17.1204 Bassa, 1996, Evaluation of preoperative chemotherapy using PET with Fluorine-18-fluorodeoxyglucose in breast cancer, J Nucl Med, 37, 931 Crippa, 1998, Prospective evaluation of Fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer, J Nucl Med, 39, 4 Smith, 1998, Staging of the axilla in breast cancer: An accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose, Ann Surg, 228, 220, 10.1097/00000658-199808000-00012 Bombardieri, 1998, Nuclear medicine approaches for detection of axillary lymph-node metastasis, Q J Nucl Med, 42, 54 Hathaway, 1999, Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent loco-regional breast cancer: Preliminary experience, Radiology, 210, 807, 10.1148/radiology.210.3.r99mr43807 Flanagan, 1998, PET in breast cancer, Semin Nucl Med, 28, 290, 10.1016/S0001-2998(98)80034-2 Hoh, 1999, 18-FDG imaging in breast cancer, Semin Nucl Med, 29, 49, 10.1016/S0001-2998(99)80029-4 Bender, 1997, Value of 18-fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma, Anticancer Res, 17, 1687 Cook, 1998, Detection of bone metastases in breast cancer by 18-FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions, J Clin Oncol, 16, 3375, 10.1200/JCO.1998.16.10.3375 Moon, 1998, Accuracy of whole-body Fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma, J Nucl Med, 39, 431 Wahl, 1993, Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation, J Clin Oncol, 11, 2101, 10.1200/JCO.1993.11.11.2101 Jansson, 1995, Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation, J Clin Oncol, 13, 1470, 10.1200/JCO.1995.13.6.1470 Oesterling, 1997, Cancer of the prostate Hoh, 1998, Positron emission tomography in urological oncology, J Urol, 159, 347, 10.1016/S0022-5347(01)63916-8 Effert, 1996, Metabolic imaging of untreated prostate cancer by positron emission tomography with 18Fluorine-labeled deoxyglucose, J Urol, 155, 994, 10.1016/S0022-5347(01)66366-3 Hofer, 1999, Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy, Eur Urol, 36, 31, 10.1159/000019923 Shreve, 1996, Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-(F-18)-fluoro-D-glucose, Radiology, 199, 751, 10.1148/radiology.199.3.8638000 Hara, 1998, PET imaging of prostate cancer using Carbon-11-choline, J Nucl Med, 39, 990 Ozols, 1997, Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma Hubner, 1993, Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-(F18) deoxyglucose (2-(18F) FDG, Gynecol Oncol, 51, 197, 10.1006/gyno.1993.1272 Buy, 1991, Epithelial tumors of the ovary: CT findings and correlation with US, Radiology, 178, 811, 10.1148/radiology.178.3.1994423 Reuter, 1998, Critical evaluation of the specificity of MRI and TVUS for differentiation of malignant from benign adnexal lesions, Eur Radiol, 8, 39, 10.1007/s003300050334 Pectasides, 1991, Correlation of abdominal computed tomography scanning and second look operation findings in ovarian cancer patients, Am J Clin Oncol, 14, 457, 10.1097/00000421-199112000-00001 Strigini, 1996, Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging and serum CA 125 assay in pre and postmenopausal women, Gynecol Oncol, 61, 68, 10.1006/gyno.1996.0098 Friedman, 1991, Second thoughts about second look laparotomy in advanced ovarian cancer, N Engl J Med, 322, 1079, 10.1056/NEJM199004123221512 Casey, 1994, Experience with positron emission tomography (PET) scans in patients with ovarian cancer, Gynecol Oncol, 53, 331, 10.1006/gyno.1994.1143 Karlan, 1993, Whole-body positron emission tomography with 2-(18F)-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma, Gynecol Oncol, 51, 175, 10.1006/gyno.1993.1268 Rohdiewicz, 1995, Indium-111 oncoscint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences: Early observations, Clin Nucl Med, 20, 230, 10.1097/00003072-199503000-00009 Bosl, 1997, Cancer of the testis Wilson, 1995, Imaging metastatic testicular germ-cell tumors with 18-FDG positron emission tomography: Prospects for detection and management, Eur J Nucl Med, 22, 508, 10.1007/BF00817273 Cremarius, 1998, FDG-PET for detection and therapy control of metastatic germ cell tumor, J Nucl Med, 39, 815 Stephens, 1996, Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients, J Clin Oncol, 14, 1637, 10.1200/JCO.1996.14.5.1637 Sugawara, 1999, Germ cell tumor: Differentiation of viable tumor, mature teratoma and necrotic tissue with FDG PET and kinetic modeling, Radiology, 211, 249, 10.1148/radiology.211.1.r99ap16249 Bajorin, 1992, Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors, Semin Oncol, 19, 148 Wahl, 1991, Imaging of renal cancer using positron emission tomography with 2-deoxy-2(18F)-fluoro-D-glucose: Pilot animal and human studies, J Urol, 146, 1470, 10.1016/S0022-5347(17)38141-7 Bachor, 1996, Positron emission tomography in diagnosis of renal cell carcinoma (in German), Urologe A, 35, 146 Miyauchi, 1996, Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings, J Nucl Med, 37, 64P Mankoff, 1997, Identification of interleukin-2-induced complete response in metastatic renal cell carcinoma by FDG-PET despite radiographic evidence suggesting persistent tumor case report, AJR Am J Roentgenol, 169, 1049, 10.2214/ajr.169.4.9308463 Hoh, 1996, Evaluation of renal cell carcinoma with whole-body FDG-PET, J Nucl Med, 37, 141P Bihl, 1999, Metastatic renal cell carcinoma: Is there a role of F-18-FDG-PET, Clin Pos Imag, 2, 340, 10.1016/S1095-0397(99)00100-4 Harney, 1991, Uptake of 2-deoxy-2-(18F) fluoro-D-glucose in bladder cancer: Animal localization and initial patient positron emission tomography, J Urol, 145, 279, 10.1016/S0022-5347(17)38314-3 Bachor, 1999, Lymph node staging of bladder neck carcinoma with positron emission tomography (in German), Urologe A, 38, 46, 10.1007/s001200050244 Kocher, 1994, Preoperative lymph-node staging in patients with kidney and urinary bladder neoplasm, J Nucl Med, 35, 223P Kosuda, 1997, Preliminary assessment of Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with bladder cancer, Eur J Nucl Med, 24, 615 Evans, 1997, Cancer of the pancreas Karl, 1993, Impact of staging on treatment of pancreatic and ampullary cancer, Endoscopy, 25, 69, 10.1055/s-2007-1009127 Muller, 1994, Pancreatic tumors: Evaluation with endoscopic US, CT and MR imaging, Radiology, 190, 745, 10.1148/radiology.190.3.8115622 Freeny, 1988, Pancreatic ductal adenocarcinoma: Diagnosis and staging with dynamic CT, Radiology, 166, 125, 10.1148/radiology.166.1.2827228 Inokuma, 1995, Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US, Radiology, 195, 345, 10.1148/radiology.195.2.7724751 Thompson, 1994, Pancreaticoduodenectomy for suspected but unproven malignancy, Ann J Surg, 169, 571, 10.1016/S0002-9610(05)80124-2 Robinson, 1996, Reoperative pancreatoduodenectomy for periampullary carcinoma, Am J Surg, 172, 432, 10.1016/S0002-9610(96)00218-8 Bares, 1994, F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer, Radiology, 192, 79, 10.1148/radiology.192.1.8208970 Stollfuss, 1995, 2-(fluorine-18)fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation, Radiology, 195, 339, 10.1148/radiology.195.2.7724750 Friess, 1995, Diagnosis of pancreatic cancer by 2(18F) fluoro-2-deoxy-D-glucose positron emission tomography, Gut, 36, 771, 10.1136/gut.36.5.771 Keogan, 1998, Diagnosis of pancreatic carcinoma: Role of FDG-PET, AJR Am J Roentgenol, 171, 1565, 10.2214/ajr.171.6.9843289 Rajput, 1998, The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease, Surgery, 124, 793, 10.1067/msy.1998.91226 Diederichs, 1998, FDG-PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies, J Nucl Med, 39, 1030 Zimny, 1997, Fluorine-18-fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases, Eur J Nucl Med, 24, 678 Rose, 1999, 18Ffluorodeoxyglucose positron emission tomography in the management of patients with suspected pancreatic cancer, Ann Surg, 229, 729, 10.1097/00000658-199905000-00016 Nakata, 1997, 18Ffluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma, Cancer, 79, 695, 10.1002/(SICI)1097-0142(19970215)79:4<695::AID-CNCR6>3.0.CO;2-D Roth, 1997, Cancer of the esophagus Yeung, 1999, FDG-PET in esophageal cancer: Incremental value over computed tomography, Clin Pos Imag, 2, 255, 10.1016/S1095-0397(99)00035-7 Luketich, 1997, Role of positron emission tomography in staging esophageal cancer, Ann Thorac Surg, 64, 765, 10.1016/S0003-4975(97)00624-3 Block, 1997, Improvement in staging of esophageal cancer with the addition of positron emission tomography, Ann Thorac Surg, 64, 770, 10.1016/S0003-4975(97)00619-X Rankin, 1998, Computed tomography and positron emission tomography in the preoperative staging of esophageal carcinoma, Clin Radiol, 53, 659, 10.1016/S0009-9260(98)80292-4 Couper, 1998, Detection of response to chemotherapy using positron emission tomography in patients with esophageal and gastric cancer, Br J Surg, 85, 1403, 10.1046/j.1365-2168.1998.00963.x Messa, 1992, Quantitative evaluation of glucose utilization in liver metastases, parametric imaging of FDG uptake with PET, J Comput Assist Tomogr, 16, 684, 10.1097/00004728-199209000-00003 Delbeke, 1998, Evaluation of benign vs malignant hepatic lesions with positron emission tomography, Arch Surg, 133, 510, 10.1001/archsurg.133.5.510 Okazumi, 1992, Evaluation of liver tumors using 18-F-fluorodeoxyglucose PET: Characterization of the tumor and assessment of the effect of the treatment, J Nucl Med, 33, 333 Torizuka, 1995, In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET, J Nucl Med, 36, 1811 Torizuka, 1994, Value of Fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy, J Nucl Med, 35, 1965 Nagata, 1990, Monitoring liver tumor therapy with 18F-FDG positron emission tomography, J Comput Assis Tomogr, 14, 370 Rojeski, 1985, Nodular thyroid disease: Evaluation and management, N Engl J Med, 331, 428, 10.1056/NEJM198508153130707 Parker, 1997, Cancer of the thyroid Shreve, 1999, Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants, Radiographics, 19, 61, 10.1148/radiographics.19.1.g99ja0761 Bloom, 1993, Determination of malignancy of thyroid nodules with positron emission tomography, Surgery, 114, 728 Uematsu, 1998, Fluorine-18-fluorodeoxyglucose PET versus Thallium-210 scintigraphy evaluation of thyroid tumors, J Nucl Med, 39, 453 Feine, 1996, Fluorine-18-FDG and Iodine-131-iodide uptake in thyroid cancer, J Nucl Med, 37, 1468 Grunwald, 1997, Comparison of 18FDG-PET with 131I iodine and 99Tc-sestamibi scintigraphy in differentiated thyroid cancer, Thyroid, 7, 327, 10.1089/thy.1997.7.327 Chung, 1999, Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan, J Nucl Med, 40, 986 Wang, 1999, (18F)-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole-body scans and elevated serum thyroglobulin levels, J Clin Endocrinol Metab, 84, 2291, 10.1210/jcem.84.7.5827 Dietlein, 1997, Fluorine-18 fluorodeoxyglucose positron emission tomography and Iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer, Eur J Nucl Med, 24, 1342, 10.1007/s002590050158 Jadvar, 1998, Evaluation of suspected recurrent papillary thyroid carcinoma with (F18) fluorodeoxyglucose positron emission tomography, Nucl Med Commun, 19, 547, 10.1097/00006231-199806000-00006 Conti, 1999, Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography, Thyroid, 9, 797, 10.1089/thy.1999.9.797 Neuman, 1994, Primary hyperparathyroidism: Preoperative parathyroid imaging with regional body FDG PET, Radiology, 192, 509, 10.1148/radiology.192.2.8029424 Musholt, 1997, Evaluation of fluorodeoxyglucose positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study, Surgery, 122, 1049, 10.1016/S0039-6060(97)90208-7 Krenning, 1993, Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe) and (123I-Tyr3)-octreotide: The Rotterdam Experience with more than 1000 patients, Eur J Nucl Med, 20, 716, 10.1007/BF00181765 Adams, 1998, Limited value of Fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours, Eur J Nucl Med, 25, 79, 10.1007/s002590050197 Shapiro, 1985, Iodine-131-metaiodobenidine for the locating of suspected pheochromocytoma: Experience in 400 cases, J Nucl Med, 26, 576 Shulkin, 1993, Pheochromocytoma that do not accumulate metaiodobenzylguanidine: Localization with PET and administration of FDG, Radiology, 186, 711, 10.1148/radiology.186.3.8430179 Neumann, 1996, Malignant pheochromocytoma of the anterior mediastinum: PET findings with (18F) FDG and 82Rb, J Comput Assist Tomogr, 20, 312, 10.1097/00004728-199603000-00028 Shulkin, 1996, Neuroblastoma: Positron emission tomography with 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy, Radiology, 199, 743, 10.1148/radiology.199.3.8637999 Vaidyanathan, 1995, Validation of 4-(Fluorine-18) fluoro-3-iodobenzylguanidine as a positron emitting analog of MIBG, J Nucl Med, 36, 644 Brennan, 1997, Soft tissue sarcoma Kern, 1988, Metabolic imaging of human extremity musculoskeletal tumors by PET, J Nucl Med, 29, 181 Adler, 1991, Noninvasive grading of musculoskeletal tumors using PET, J Nucl Med, 32, 1508 Griffeth, 1992, PET evaluation of soft tissue masses with Fluorine-18 fluoro-2-deoxy-D-glucose, Radiology, 182, 185, 10.1148/radiology.182.1.1727280 Nieweg, 1996, Fluorine-18-fluorodeoxyglucose PET imaging of soft tissue sarcomas, J Nucl Med, 37, 257 Eary, 1998, Quantitative (F-18) fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma, Clin Cancer Res, 4, 1215 Dehadashti, 1996, Benign versus malignant intraosseous lesions: Discrimination by means of PET with 2-(F-18) fluoro-2-deoxy-D-glucose, Radiology, 200, 243, 10.1148/radiology.200.1.8657920 Kole, 1998, Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors, J Nucl Med, 39, 810 Lucas, 1998, Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft tissue sarcomas, J Bone Joint Surg Br, 80, 441, 10.1302/0301-620X.80B3.8232 Jones, 1996, Monitoring of neoadjuvant therapy response of soft tissue and musculoskeletal sarcoma using Fluorine-18, FDG-PET, J Nucl Med, 37, 1438 Van Ginkel, 1996, FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft tissue sarcoma, J Nucl Med, 37, 984 Shulkin, 1995, Neoplasms in a pediatric population: 2-(F-18)-fluoro-2-deoxy-D-glucose PET studies, Radiology, 194, 495, 10.1148/radiology.194.2.7824731 Hoffman, 1992, FDG-PET in pediatric posterior fassa brain tumors, J Comput Assist Tomogr, 16, 62, 10.1097/00004728-199201000-00011 Delbeke, 1995, Optimal cut-off levels of F-18 fluorodeoxyglucose uptake in the differentiated of low grade from high grade brain tumors with PET, Radiology, 195, 47, 10.1148/radiology.195.1.7892494 Fauci, 1998, Human immunodeficiency virus (HIV) disease: AIDS and related disorders Hoffman, 1993, FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS, J Nucl Med, 34, 567 O'Doherty, 1997, PET scanning and the human immunodeficiency virus-positive patient, J Nucl Med, 38, 1575 Villringer, 1995, Differentialdiagnosis of CNS lesions in AIDS patients by FDG PET, J Comput Assist Tomogr, 19, 532, 10.1097/00004728-199507000-00004 Ernst, 1998, Cerebral toxoplasmosis and lymphoma in AIDS: Perfusion MR imaging experience in 13 patients, Radiology, 208, 663, 10.1148/radiology.208.3.9722843 Higashi, 1993, In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy, J Nucl Med, 34, 773 Haberkorn, 1992, Metabolic design of combination chemotherapy: Use of enhanced fluorodeoxyglucose uptake caused by chemotherapy, J Nucl Med, 33, 1981 Rozental, 1989, Glucose uptake by gliomas after treatment. A positron emission tomographic study, Arch Neurol, 46, 1302, 10.1001/archneur.1989.00520480044018 DeWitte, 1994, Acute effects of carmustine on glucose metabolism in brain and glioblastoma, Cancer, 74, 2836, 10.1002/1097-0142(19941115)74:10<2836::AID-CNCR2820741015>3.0.CO;2-M De-Reuck, 1999, (Methyl-11C) thymidine positron tomography in tumoral and non-tumoral cerebral lesions, Acta Neurol Belg, 99, 118 Shields, 1996, Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging, J Nucl Med, 37, 290 Goethals, 1996, (Methylcarbon-11)-thymidine for in vivo measurement of cell proliferation, J Nucl Med, 37, 1048 Larson, 1981, Positron imaging feasibility studies: Part 1. Characteristics of H-3-thymidine uptake in rodent and canine neoplasms-concise communication, J Nucl Med, 22, 869 Senekowitsch-Schmidtke, 1999, Radiolabeled thymidine: A sensitive tracer for early tumor response and recurrence after irradiation, J Nucl Med, 40, 1702 Heiss, 1999, Investigation of transport mechanism and uptake kinetics of O-(2-(18-F)fluoroethyl)-L-tyrosine in vitro and in vivo, J Nucl Med, 40, 1367 Jonson, 1998, PET imaging of breast cancer with Fluorine-18 radiolabeled estrogens and progestins, Q J Nucl Med, 42, 8 Mintum, 1988, Breast cancer: PET imaging of estrogen receptors, Radiology, 169, 45, 10.1148/radiology.169.1.3262228 McGuine, 1991, Positron tomographic assessment of 16α-(F18)-fluoro-17β estradiol uptake in metastatic breast carcinoma, J Nucl Med, 32, 1526 Mortimer, 1996, Clinical correlation of FDG and FES-PET imaging with estrogen receptor and response to systemic therapy, Clin Cancer Res, 2, 933 Dehdashti, 1999, Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy, Eur J Nucl Med, 26, 51, 10.1007/s002590050359 Moresco, 1997, Oestrogen receptors in meningiomas: A correlative PET and immunohistochemical study, Nucl Med Commun, 18, 606, 10.1097/00006231-199707000-00003 Moehler, 1998, 18F labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil, Cancer, 83, 245, 10.1002/(SICI)1097-0142(19980715)83:2<245::AID-CNCR7>3.0.CO;2-P Dimitrakopoulou-Strauss, 1998, Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma, J Nucl Med, 39, 465